Changes in the liver transplant evaluation process during the early COVID-19 era and the role of telehealth

Table 2 Predictors of telehealth use among outpatients during the coronavirus disease 2019 era

	Univariable OR (95%CI)	P value	Multivariable OR (95%CI)	P value
Age (per year increase)	1.01 (0.98-1.05)	0.46	1.01 (0.96-1.05)	0.78
Sex, male	0.58 (0.27-1.24)	0.16	0.64 (0.26-1.59)	0.34
Preferred language, non-English	0.91 (0.39-2.11)	0.82	0.97 (0.31-3.02)	0.97
Race/ethnicity (ref: White)
Hispanic	0.67 (0.30-1.49)	0.33	0.64 (0.23-1.78)	0.39
Asian	1.40 (0.44-4.45)	0.57	2.01 (0.47-8.56)	0.34
Other	0.47 (0.08-2.75)	0.4	0.34 (0.03-3.94)	0.39
Insurance (ref: Private)
Medicare	1.92 (0.83-4.46)	0.13	1.85 (0.61-5.62)	0.28
Medi-cal	1.86 (0.72-4.80)	0.2	1.73 (0.55-5.40)	0.35
MELD-Na at evaluation (per unit increase)	0.97 (0.91-1.03)	0.3	0.96 (0.89-1.04)	0.29
Distance to Stanford Hospital (per 50 miles)	0.93 (0.76-1.14)	0.48	0.94 (0.74-1.20)	0.62
Alcohol etiology	1.38 (0.67-2.85)	0.38	1.96 (0.78-4.90)	0.15
HCC diagnosis	1.11 (0.52-2.36)	0.8	0.67 (0.23-1.98)	0.47

MELD-Na: Model for end-stage liver disease with sodium; HCC: Hepatocellular carcinoma.